Private Labels, Public Consequences: Making Sense of the Stelara Biosimilar Market in 2025

Beyond the Bag: Building Operational Resilience in Your Buy-and-Bill Infusion Model

Accumulator and Maximizer Programs: What Specialty Providers Need to Know About the Hidden Costs for Patients

The Growing Impact of Payer Mandates on Specialty Pharmacy Access

Optimizing Drug Procurement

Vertical Integration and the Future of Buy-and-Bill: How Wholesalers Are Rewriting Market Access

Biosimilar Adoption in 2026: What Every Specialty Practice Needs to Know

Optimizing Infusion Center Capacity in 2026: Strategies to Do More Without Expanding Footprint

Faster Rituximab Infusions in Rheumatology: Evidence Supports Safe, Efficient Care Delivery